Reports Q3 revenue $25.2M, consensus $370,000. As of September 30, 2023, cash, cash equivalents and investments totaled $810.6M compared to approximately $1B as of December 31, 2022. Relay Therapeutics expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RLAY:
- Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
- Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
- Relay Therapeutics price target raised to $33 from $30 at H.C. Wainwright
- Relay: Lirafugratinib data show durable response across multiple FGFR2 tumors
- Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
